PharmPK Discussion - Effect of Dosing Vehicle on Pharmacokinetics

• On 31 Aug 1996 at 22:43:21, Teruaki Okuda (tokuda.aaa.inetmie.or.jp) sent the message
  

  
  I would like to know the effect of dosing vehicle used to intravenous
  administration on pharmacokinetics(plasma concentration).  For example, when a
  drug is administratetd as saline or PEG-400 solution, whether would the
  pharmacokinetics of durg be same between the two vehicles.
  
  

  Back to the Top

• On 2 Sep 1996 at 22:50:02, Richard Molitor (rmolitor.at.u.washington.edu) sent the message
  

  
  On Sat, 31 Aug 1996, Teruaki Okuda wrote:
  
  > PharmPK - Discussions about Pharmacokinetics
  >  Pharmacodynamics and related topics
  >
  > I would like to know the effect of dosing vehicle used to intravenous
  > administration on pharmacokinetics(plasma concentration).  For example, when a
  > drug is administratetd as saline or PEG-400 solution, whether would the
  > pharmacokinetics of durg be same between the two vehicles.
  >
  Since the route of administration is intravenous (avoiding the Absorption
  phase) my initial thought isn't so much kinetics vs. chemistry &
  toxicology.  A drug that's stable in saline wouldn't really need to be
  administered in PEG-400 would it?
  
  Richard Molitor, R.Ph.
  Seattle, Wa
  
  

  Back to the Top

• On 2 Sep 1996 at 22:50:07, "David S. Farrier" (dfarrier.-at-.bright.net) sent the message
  

  
  At 10:43 PM 8/31/96 -0500, you wrote:
  >PharmPK - Discussions about Pharmacokinetics
  > Pharmacodynamics and related topics
  >
  >I would like to know the effect of dosing vehicle used to intravenous
  >administration on pharmacokinetics(plasma concentration).  For example, when a
  >drug is administratetd as saline or PEG-400 solution, whether would the
  >pharmacokinetics of durg be same between the two vehicles.
  >
  Teruaki Okuda,
  
  The "safe" answer to your question is: if the vehicle does not (1) change
  the dissociation of the drug through pH effects, (2) dose not effect binding
  of the drug (e.g., to exipients in the vehicle), (3) does not unduly alter
  the initial concentration of drug in the bolus, and (4) the vehicle has no
  vascular effects of its own, then the initial absorption and ultimate plasma
  concentration curves should not vary noticibly between vehicles, at least
  within the typical variance associated with dosing and sampling.
  
  David
  ..
  Dr. David S. Farrier
  Summit Research Services
  1374 Hillcrest Drive
  Ashland, OH 44805
  USA
  (419)-289-9207
  E-mail: dfarrier.aaa.bright.net
  
  

  Back to the Top

Copyright 1995-2014 David W. A. Bourne (david@boomer.org)